This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
The supplements are made using only vegetarian-sourced ingredients
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The approval is backed by data showing deep, durable responses and manageable tolerability
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Subscribe To Our Newsletter & Stay Updated
